The sterilant didn't change. Its category did.

Pull a 510(k) for any device labeled sterile and the sterilization section reads like a checklist: method, cycle, validation data, sterility assurance level. What that checklist actually demands depends on a fact that never shows up as its own field — which of three tiers FDA has sorted the method into. In January 2024, one method moved tiers without changing a single thing about how it sterilizes a device.

What the three tiers measure

FDA’s guidance on sterility information in 510(k) submissions sorts every sterilization method into one of three categories, and the category is what decides how much a submission has to prove. Established Category A covers methods with a long history of safe and effective use and an FDA-recognized consensus standard behind them — moist heat, dry heat, ethylene oxide in a fixed chamber, radiation. Established Category B covers methods FDA has already reviewed data for, cycle by cycle, but that have no recognized consensus standard reaching that specific use. Novel covers everything else: new sterilants, new combinations, or a changed parameter on an established method that FDA hasn’t previously reviewed or cleared. Three devices sterilized by three different methods can carry an identical biological outcome and still owe FDA three different weights of paperwork, because the categories measure the method’s regulatory history, not the result.

What moved, and why

Vaporized hydrogen peroxide sterilized devices for years under Established Category B — FDA had reviewed specific VHP cycles before, but no recognized consensus standard covered the method itself. That changed on May 29, 2023, when FDA’s Recognized Consensus Standards database added ISO 22441:2022, the standard governing low-temperature VHP sterilization, with full recognition. On January 8, 2024, FDA revised the 510(k) sterility guidance to list VHP as an example of an Established Category A method. The device didn’t change. The validation science didn’t change. What changed was that a consensus standard now existed for FDA to point to, and the guidance moved the method to the tier that requires one.

A method’s category is a record of what FDA has recognized about it, not a property of the sterilant itself. The same gas, reviewed before a standard existed and reviewed again after, sits in two different places in the same guidance document.

Why the tier is the lever

The practical weight falls on what a 510(k) has to submit, not on what the device has to achieve. Every device labeled sterile still has to support a sterility assurance level of 10⁻⁶ — 10⁻³ is the guidance’s own exception, reserved for devices that contact only intact skin. That bar doesn’t move with the category. What moves is the burden of proving a given cycle meets it: an Established Category A submission can rely on conformance to the recognized standard and a validation summary; Established Category B still needs FDA to review the specific cycle data directly; Novel needs the fullest record the guidance asks for, because nothing about the method has a track record FDA can lean on. Moving VHP into Category A didn’t lower the sterility bar for a single device. It shortened the path to showing a VHP-sterilized device clears it.

The practice

A sponsor reading an older VHP submission file, or benchmarking a competitor’s clearance against today’s expectations, is comparing two different regulatory postures on the same gas — one written when the category was B, one written after it became A. openFDA’s clearance record has no field for which sterilization category a device’s 510(k) relied on, the same way it has none for the Human Factors submission category this blog has described elsewhere. Reading the category a given clearance actually claimed is still a judgment that starts with the guidance document and the recognition database, not a lookup — and whether an alternative method or SAL for a specific device needs a pre-submission conversation with FDA, which the guidance itself recommends for anything outside its tiers, is a call for the regulatory professional on that file, never this post.

FDA Radar doesn’t monitor the Recognized Consensus Standards database as a continuous feed today — see what we monitor and what we deliberately don’t. Until it does, checking a method’s current category before citing it in a submission stays a manual step, same as checking a clause-level recognition exclusion before citing any other standard.